Bringing Rationalism to Empiricism: A Discussion on Empiric SBRT for Early-Stage Lung Cancer

Lung cancer screening is resulting in a higher incidence of early-stage lung cancer diagnoses. This commonly occurs among older patients with chronic lung disease who are at high risk for complications with attaining pathologic confirmation. This activity reviews Empiric Radiotherapy for Lung Cancer Collaborative Group consensus guidelines on when to offer empiric SBRT for radiographic early-stage lung cancer.

This activity is available from October 22, 2024, through 11:59 p.m. Eastern time on October 21, 2026. 

Target Audience

The activity is designed to meet the interests of radiation oncologists, medical oncologists, surgeons, diagnostic pathologists, and residents.   

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Feel confident providing empiric lung SBRT in the appropriate context.
  • Discuss the competing risks of biopsy, empiric surgery, empiric SBRT, and continued surveillance.
Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 0.50 Certificate of Attendance
    This activity was designated for 0.50 AMA PRA Category 1 Credit™.
Course opens: 
10/22/2024
Course expires: 
10/21/2026
Cost:
$149.00
Rating: 
0
  • Laura Dover, MD, is employed by Ascension St. Vincent's East Cancer Treatment Center. Dr. Dover serves as a member of the Editorial Board for Practical Radiation Oncology.

The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification. 

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 0.50 Certificate of Attendance
    This activity was designated for 0.50 AMA PRA Category 1 Credit™.

Price

Cost:
$149.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

Nonmember: $149
Member: $99
Member-in-training: $49
Student/Grad Student/PGY Member: $49
Postdoctoral Fellow Member: $49

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.

Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.

The course and its materials will only be available on the ASTRO website until October 21, 2026, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.